M&I Professor, Dr. Huang-Ge Zhang, recently received an R01 titled "Mechanisms Underlying Edible Exosome-Like Nanoparticles for Prevention of Brain Inflammation."  The grant, funded by the National Center for Complementary and Integrative Health, is budgeted until 2027 for a total amount of $3,328,110. 

 Dr. Zhang also recently received a merit review award titled “RA synovial fibroblast exosomes (RA-EXo) mediated bone erosion via AhR/TRAF2pathway”. The grant, funded by Biomedical Laboratory of Research and Development, Department of Veterans Affairs, is budgeted until 2026 for a total amount of $1,032,665.

M&I Associate Professor, Dr. Donghoon Chung, was awarded an NIH grant titled "Midwest AViDD center – Project 5, anti-viral helicase inhibitor." The Chung lab will discover and develop antivirals targeting viral helicases of SARS-CoV2 and other potential pandemic viruses as part of the Midwest AViDD centner, one of nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern established by NIH. (https://www.nih.gov/news-events/news-releases/nih-announces-antiviral-drug-development-awards). Chung is awarded a total of $3.73M for next three years (2022-2055) with potential 2 years of additional funding (up to $2.7M) based on the progress and the availability of funds.

Dr. Chung also received an award titled "Mechanism of action and resistance to NHC by Chikungunya virus" to study how to address the development of broad-spectrum antivirals against emerging RNA viruses with the lethal mutagenesis theory. The grant, funded by Merck and Co., Inc., is budgeted until 2023 for a total of $312,000.